Age-related Macular Degeneration Market Size, Share, Growth Analysis, By Product, By Molecule, By Approval Type, By Type of AMD By End User, By Region - Industry Forecast 2024-2031

Global Age-related Macular Degeneration Market size was valued at USD 9.2 billion in 2022 and is poised to grow from USD 10.19 billion in 2023 to USD 23.16 billion by 2031, growing at a CAGR of 10.80% during the forecast period (2024-2031).

Age-related macular degeneration (AMD), a leading cause of vision loss in the elderly, primarily affects the macula, the central area of the retina. The two prevalent forms of AMD-dry and wet-differ significantly in their progression and treatment approaches. Dry AMD is more common, often managed through lifestyle changes and vitamin supplementation, whereas wet AMD, though rarer, necessitates more invasive treatments, including anti-VEGF injections that directly target the abnormal blood vessel growth beneath the macula. This treatment method effectively inhibits the proteins responsible for such growth, illustrating the nuanced medical interventions required for different AMD types. As the global population ages, the market for AMD treatments is expanding, driven largely by the increasing prevalence of the disease among seniors and their growing reliance on medication. This trend underscores the importance of tailored healthcare solutions as more individuals seek to maintain their vision. Consequently, the surge in AMD cases, alongside advancements in pharmaceutical interventions, suggests a robust market trajectory for AMD therapies. With a rising number of seniors adopting lifestyle adjustments and medication for AMD management, the market is poised for sustained growth, indicating a significant opportunity for healthcare providers and pharmaceutical companies to innovate and expand their AMD treatment offerings in response to the evolving needs of this demographic.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Age-Related Macular Degeneration market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Age-Related Macular Degeneration Market Segmental Analysis

Global Age-related Macular Degeneration Market is segmented by Product, Molecule, Approval Type, Type of AMD, End User, and region. Based on Product, the market is segmented into Eylea & Eylea HD, Lucentis, Vabysmo, Syfovre, and Other Products. Based on Molecule, the market is segmented into Aflibercept, Faricimab, Ranibizumab, Pegcetacoplan, and Other Molecules. Based on Approval Type, the market is segmented into Biologics, and Biosimilars. Based on Type of AMD, the market is segmented into Wet AMD, and Dry AMD. Based on End User, the market is segmented into Hospitals, Long-Term Care Facilities, Specialty Centers, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Age-Related Macular Degeneration Market

The global age-related macular degeneration (AMD) market is significantly driven by the increasing elderly population, as this demographic is more vulnerable to the onset of AMD due to age-related physiological changes. As life expectancy continues to rise globally, the prevalence of AMD is expected to escalate, leading to a heightened demand for effective therapies and treatments aimed at managing and preventing vision loss. This surge in cases not only emphasizes the need for advanced medical solutions but also stimulates innovation and investment in research and development of AMD-targeted interventions, thereby propelling the overall market growth and addressing the impending vision health crisis among seniors.

Restraints in the Global Age-Related Macular Degeneration Market

One significant market restraint for the global age-related macular degeneration (AMD) market is the inadequate screening and diagnostic infrastructure in many regions. This deficiency not only leads to poor patient outcomes but also causes treatment delays, as individuals often remain unaware of their condition until it progresses to a more severe stage. The lack of awareness and information regarding available diagnostic tools further exacerbates this issue, limiting early interventions that are crucial for effective management of AMD. Consequently, the inefficiencies in current therapeutic options arise, stifling overall market growth and hindering advancements in patient care for AMD.

Market Trends of the Global Age-Related Macular Degeneration Market

The Global Age-Related Macular Degeneration (AMD) market is witnessing a significant trend towards the development and adoption of long-acting therapies, particularly extended-duration anti-VEGF treatments. This shift aims to address longstanding compliance issues associated with frequent injection schedules, as these innovative therapies reduce the treatment burden on patients by extending the duration between doses. By enhancing patient adherence and improving clinical outcomes, long-acting therapies are poised to drive market growth amidst previous challenges faced by conventional treatments. As a result, the AMD market is evolving with a focus on patient-centered solutions, indicating a promising future for therapeutic innovations in this domain.